Harry is the product lead for genomics at NVIDIA, leveraging NVIDIA’s expertise in AI, high performance computing (HPC), and data analytics stacks to address genomics workflows with accelerated high-accuracy solutions. His background is in bioinformatics and functional genomics, including a PhD from the University of Oxford, post-doctoral experience in the biopharma industry and at the University of Cambridge, and entrepreneurial experience in the biotech sector. Harry was listed in Forbes’ 30 Under 30 after co-founding precision oncology company CCG.ai (acquired by Dante Labs), a Y Combinator and Merck Accelerator-backed start-up delivering decision support via deep learning and advanced analytical software.